These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 35352187)

  • 21. Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review.
    Jurca CM; Iuhas O; Kozma K; Petchesi CD; Zaha DC; Bembea M; Jurca S; Paul C; Jurca AD
    Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New treatments for rare bone diseases: hypophosphatemic rickets/osteomalacia.
    Marques JVO; Moreira CA; Borba VZC
    Arch Endocrinol Metab; 2022 Nov; 66(5):658-665. PubMed ID: 36382755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Congenital Conditions of Hypophosphatemia Expressed in Adults.
    Marcucci G; Brandi ML
    Calcif Tissue Int; 2021 Jan; 108(1):91-103. PubMed ID: 32409880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report.
    Toi N; Imanishi Y; Nagata Y; Kurajoh M; Morioka T; Shoji T; Shinto Y; Emoto M
    Endocr J; 2023 Apr; 70(4):419-426. PubMed ID: 36575021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in understanding of phosphate homeostasis and related disorders.
    Michigami T
    Endocr J; 2022 Aug; 69(8):881-896. PubMed ID: 35831119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C-Terminal Fibroblast Growth Factor-23 Levels in Non-Nutritional Hypophosphatemic Rickets.
    Bharati J; Bhatia D; Khandelwal P; Gupta N; Sinha A; Khadgawat R; Hari P; Bagga A
    Indian J Pediatr; 2019 Jun; 86(6):555-557. PubMed ID: 30835073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet.
    Raeder H; Shaw N; Netelenbos C; Bjerknes R
    Eur J Endocrinol; 2008 Dec; 159 Suppl 1():S101-5. PubMed ID: 18775977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
    Drezner MK; Lyles KW; Haussler MR; Harrelson JM
    J Clin Invest; 1980 Nov; 66(5):1020-32. PubMed ID: 6253520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mineralized tissues in hypophosphatemic rickets.
    Robinson ME; AlQuorain H; Murshed M; Rauch F
    Pediatr Nephrol; 2020 Oct; 35(10):1843-1854. PubMed ID: 31392510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.
    Balani S; Perwad F
    Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):531-536. PubMed ID: 32701599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders.
    Ramos P; Larson B; Ashrafzadeh-Kian S; Ito N; Kato H; Bornhorst JA; Algeciras-Schimnich A
    Endocr Pract; 2023 Mar; 29(3):193-198. PubMed ID: 36627024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium.
    Laurent MR; De Schepper J; Trouet D; Godefroid N; Boros E; Heinrichs C; Bravenboer B; Velkeniers B; Lammens J; Harvengt P; Cavalier E; Kaux JF; Lombet J; De Waele K; Verroken C; van Hoeck K; Mortier GR; Levtchenko E; Vande Walle J
    Front Endocrinol (Lausanne); 2021; 12():641543. PubMed ID: 33815294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
    Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
    J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report.
    Takashi Y; Toyokawa K; Oda N; Muta Y; Yokomizo H; Fukumoto S; Kawanami D
    Front Endocrinol (Lausanne); 2022; 13():1004624. PubMed ID: 36531500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired Growth Plate Maturation in XLH Is due to Both Excess FGF23 and Decreased 1,25-Dihydroxyvitamin D Signaling.
    Yadav PS; Kobelski MM; Martins JS; Tao T; Liu ES; Demay MB
    Endocrinology; 2023 Nov; 165(1):. PubMed ID: 38066669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked Hypophosphatemia.
    Ewert A; Rehberg M; Schlingmann KP; Hiort O; John-Kroegel U; Metzing O; Wühl E; Schaefer F; Kemper MJ; Derichs U; Richter-Unruh A; Patzer L; Albers N; Dunstheimer D; Haberland H; Heger S; Schröder C; Jorch N; Schmid E; Staude H; Weitz M; Freiberg C; Leifheit-Nestler M; Zivicnjak M; Schnabel D; Haffner D
    J Clin Endocrinol Metab; 2023 Sep; 108(10):e998-e1006. PubMed ID: 37097907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets.
    Alon US; Levy-Olomucki R; Moore WV; Stubbs J; Liu S; Quarles LD
    Clin J Am Soc Nephrol; 2008 May; 3(3):658-64. PubMed ID: 18256372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic and clinical profile of patients with hypophosphatemic rickets.
    Marik B; Bagga A; Sinha A; Khandelwal P; Hari P; Sharma A
    Eur J Med Genet; 2022 Aug; 65(8):104540. PubMed ID: 35738466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia.
    Imanishi Y; Ito N; Rhee Y; Takeuchi Y; Shin CS; Takahashi Y; Onuma H; Kojima M; Kanematsu M; Kanda H; Seino Y; Fukumoto S
    J Bone Miner Res; 2021 Feb; 36(2):262-270. PubMed ID: 32967046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypophosphatemic Rickets.
    Bitzan M; Goodyer PR
    Pediatr Clin North Am; 2019 Feb; 66(1):179-207. PubMed ID: 30454743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.